There is evidence that the non‐rising trajectory of NfL in bio‐fluids during disease progression may simply reflect more efficient clearance by the immune response, as raising anti‐NfL antibodies in a more advanced disease stage has been reported in ALS (Puentes et al. Here, NEFL is linked to amyotrophic lateral sclerosis.